Batavia Biosciences
A Center of Excellence in Biopharmaceutical Manufacturing

The biopharmaceutical industry continues to forge ahead with innovation, striving to create better and more effective products. But the journey of a product from conception to the patient’s bedside is a complex, demanding, and often protracted process.

Batavia Biosciences, a renowned CDMO, addresses this challenge by offering bespoke services from development to GMP manufacturing for viral vectors, vaccines, and recombinant proteins.

Batavia embraces the customer intimacy model to be a thought partner to its clients, guiding them in transitioning complex biotechnology-based products, particularly biopharmaceuticals, from the lab to clinical success. The commitment to this model positions the company as a center of excellence in biopharmaceutical R&D and clinical manufacturing.

Unlike other CDMOs that adopt a more vendor-centric approach, Batavia’s approach goes beyond mere execution. The combination of expertise, biological materials, innovative solutions, extensive in-house experience, and cutting-edge technology platform enables it to guide clients toward success with speed and precision.

Batavia does not just focus on the immediate project but understands a client’s end game. This paves the way for scalable commercial manufacturing.

“Clients typically approach us to deal with three different challenges, including yield issues, scale-up problems, and product stability concerns,” says Menzo Havenga, CEO, Batavia. “Our cutting-edge technologies Hip-Vax, SIDUS, SCOUT, SATIRN, and STEP are tailored to address different issues.”

Batavia’s HIP-Vax technology is a low-cost viral vector manufacturing platform that produces viral vector products like gene therapy and oncolytic virotherapy. In the realm of viral vector-based products, Batavia has the SIDUS platform, offering meticulously crafted protocols for transient transfection across a range of cell lines and various bioreactors. The STEP technology has been patented and can be licensed out to clients that require high yields of protein and antibody on a per-cell basis. This helps achieve remarkably enhanced yields of viral vectors, setting a new standard for excellence in the industry.

The capabilities of the cutting-edge solutions are complemented by a methodical approach to product development. The initial phase begins with process development in the research and development (R&D) stage. This stage focuses on creating a recipe that outlines the production and purification of the biopharmaceutical products. It also entails the development of testing and assays to evaluate the production, integrity, and presence of contaminants. Once the R&D phase is over, a well-defined process is established and translated into a clinical batch, which represents an experimental medicine that can be tested on human subjects. Following this, clinical trials are initiated, which progresses through phase 1,2, and 3.

In one instance, Bill and Melinda Gates Foundation approached Batavia to produce global health vaccines at affordable cost. The company, leveraging its state-of-the-art technology, reduced the production expenses for the Trivalent polio vaccine, containing three distinct polio strains. This achievement was not limited to polio; it also assisted in providing measles and rubella vaccines, contributing significantly to the foundation’s efforts to enhance global health accessibility.

Batavia extends its services not just to large companies but even to startups. Its ‘Guidance to PDP’ service helps startups create a robust product development plan, allowing entrepreneurs to seek financial stability and a clear path to success in the biopharmaceutical industry.

Batavia Biosciences continues to remain a beacon of innovation in the biopharmaceutical space. As part of global family companies of CJ CheilJedang, a leading player of global amino-acid market, has turned it into a one-stop shop, offering a full range of services throughout biopharmaceutical development and manufacturing trajectory. This unwavering commitment to clients, innovative solutions to industry challenges, and dedication to employee growth and social responsibility have cemented Batavia’s leadership position in the market.